Skip to content
Sakar Healthcare logo

Sakar Healthcare

SAKAR NSE
₹979.50 +34.95 (+3.70%)
P/E
60.39
View as Markdown
MCP
Close 4 Nov 2026 ₹979.50 +589.40 +151% 1Y
Start ₹390.10

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
12.40%
Debt to Equity
0.22
EPS (TTM)
₹16.22
Book Value
₹155.50
Market Cap
—
P/E (TTM)
60.39
P/B
6.30
ROE
9.99%
Dividend Yield
0.00%
EBITDA
₹71.20 Cr
52W High
₹1,229.85
52W Low
₹352.50
Day Range
₹937.05 – ₹984.00
Volume
93,831

Peer Comparison

Healthcare › Pharmaceuticals

Sakar Healthcare peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Sakar Healthcare (this company)
₹979.5060.39₹2,091 Cr6.300.00%9.99%12.40%₹272 Cr₹36 Cr
Median 8 companies₹1,587.7049.60₹1,25,337 Cr5.540.44%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 100/100

surveillance:ASM1insider_selling

Category scores

Quality
62
Good
Returns, margins, earnings quality 22% weight
Valuation
29
Poor
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
64
Good
Solvency, leverage, coverage 9% weight
Momentum
84
Strong
Trend strength, vol-adjusted 12% weight
Ownership
62
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 23.1% CAGR over last 5 years
  • Company's median sales growth is 18.0% of last 10 years

Weaknesses

4
  • Stock is trading at 6.41 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Promoter holding has decreased over last quarter: -0.82%
  • Company has a low return on equity of 7.49% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3610
OscillatorsBullish162
Moving AveragesStrong Bullish208

Key readings

RSI (14)
49.81
Neutral
MACD (12,26,9)
−22.02
Bullish
SMA (50)
1,019.89
Bearish
SMA (200)
753.45
Bullish

As of

Analyst Rating

Based on 1 analysts
BUY100%

1 of 1 analyst rates Buy, 0 Hold, 0 Sell.

As of

BUY
1
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+19.86%
5Y+21.45%
3Y+23.58%
1Y+41.01%
TTM+43.92%

Net profit

Net profit growth by window
10Y+31.10%
5Y+22.22%
3Y+32.15%
1Y+66.67%
TTM+71.43%

Operating cash flow

Operating cash flow growth by window
10Y+18.47%
5Y+26.71%
3Y+14.08%
1Y+44.12%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+7.98 pp
5Y+3.28 pp
3Y+2.68 pp
1Y−0.60 pp
TTM+0.27 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹44.00 Cr
Mar 2018₹53.00 Cr
Mar 2019₹68.00 Cr
Mar 2020₹83.00 Cr
Mar 2021₹95.00 Cr
Mar 2022₹128 Cr
Mar 2023₹133 Cr
Mar 2024₹153 Cr
Mar 2025₹178 Cr
Mar 2026₹251 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹3.00 Cr
Mar 2018₹4.00 Cr
Mar 2019₹7.00 Cr
Mar 2020₹10.00 Cr
Mar 2021₹11.00 Cr
Mar 2022₹15.00 Cr
Mar 2023₹13.00 Cr
Mar 2024₹12.00 Cr
Mar 2025₹18.00 Cr
Mar 2026₹30.00 Cr

Analyst Forecasts

Forecast For
FY27 consensus · EBITDA
₹96.70 Cr +35.8% vs FY26
Reported High Mean Low

Quarterly Results

₹ Cr
SAKAR quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
39
34
37
43
41
43
43
50
53
58
70
71
73
87
Expenses
30
25
28
32
30
31
32
35
40
46
52
45
52
63
Operating Profit
9
9
9
11
11
12
12
16
13
11
19
26
21
24
OPM %
23%
27%
24%
25%
26%
27%
27%
31%
24%
20%
26%
37%
29%
28%
Other Income
2
1
0
1
0
0
0
0
0
1
1
0
2
0
Interest
2
2
2
2
1
2
1
4
2
2
2
2
2
2
Depreciation
5
4
4
5
5
5
5
5
6
6
6
6
7
7
PBT
4
4
3
5
5
5
5
6
5
5
11
18
15
16
Tax %
28%
13%
31%
35%
49%
6%
17%
8%
13%
15%
6%
39%
29%
29%
Net Profit
3
4
2
3
2
5
5
6
5
5
10
11
10
11
EPS (₹)
1.49
1.7
0.95
1.43
1.11
2.21
2.06
2.62
2.1
2.04
4.61
4.95
4.62
—

Sep 2026: from the results filed on 23 Oct 2026, ahead of the full statement, so some rows are blank.

Profit & Loss

₹ Cr
SAKAR profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
35
41
44
53
68
83
95
128
133
153
178
252
272
Expenses
27
33
34
40
51
63
72
99
100
115
128
182
195
Operating Profit
8
8
10
13
17
20
23
29
33
38
50
69
77
OPM %
22%
20%
23%
24%
25%
24%
24%
23%
25%
25%
28%
27%
28%
Other Income
0
0
1
0
1
2
1
2
5
3
1
2
3
Interest
3
3
3
3
2
2
2
3
6
8
9
8
7
Depreciation
2
3
3
4
6
7
8
10
15
18
21
24
25
PBT
2
3
5
6
9
12
13
19
17
16
22
40
49
Tax %
24%
22%
30%
38%
28%
21%
19%
20%
24%
27%
19%
23%
—
Net Profit
2
2
3
4
7
10
11
15
13
12
18
30
36
EPS (₹)
2.3
2.78
3.08
3.12
4.47
6.43
6.84
8.9
6.7
5.37
7.97
13.7
16.22
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
SAKAR balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
8
8
11
12
15
15
16
17
19
22
22
22
Reserves
7
11
25
39
57
66
83
110
154
241
264
302
Borrowings
25
22
24
11
11
17
43
93
119
79
86
71
Other Liabilities
11
10
11
18
15
17
37
47
44
47
43
86
Total Liabilities
50
51
71
81
97
115
178
268
336
389
415
481
Fixed Assets
36
37
49
53
64
66
69
205
267
314
309
326
CWIP
0
0
0
0
9
13
49
1
6
0
17
4
Investments
0
0
0
0
0
0
0
7
3
0
0
0
Other Assets
14
14
22
28
25
36
60
55
60
74
90
151
Total Assets
50
51
71
81
97
115
178
268
336
389
415
481

Cash Flow

₹ Cr
SAKAR cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
4
9
2
5
16
19
15
36
33
24
34
49
Investing
−1
−4
−14
−8
−25
−22
−47
−90
−74
−52
−31
−28
Financing
−3
−6
13
−13
9
3
32
55
41
27
−3
−21
Net Cash Flow
1
−1
0
−16
0
0
0
0
0
0
0
0
Free Cash Flow
4
5
−13
−4
−9
−4
−32
−62
−49
−35
2
21
CFO/EBITDA
60
117
30
51
104
110
67
121
113
72
73
77

Ratios

SAKAR financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
21
26
44
74
51
36
48
40
60
50
63
73
Inventory Days
142
107
114
51
70
92
112
69
76
121
193
207
Days Payable
20
66
51
57
41
46
141
149
129
120
93
153
Cash Conversion Cycle
143
67
107
68
80
83
19
−39
7
51
163
127
Working Capital Days
27
10
67
98
31
31
2
−11
−6
29
52
45
ROCE %
14%
14%
15%
14%
16%
16%
13%
12%
9%
7%
9%
12%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Sakar Healthcare insights

65 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 51.70%
  • Public 20.42%
  • FIIs 12.34%
  • DIIs 11.92%
  • Others 3.63%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Not shown for some quarters: FIIs and Others. Not available separately for this quarter: the holding is recorded inside Others, so both are left blank rather than shown at a wrong split.

Documents

Frequently Asked Questions about Sakar Healthcare

What does Sakar Healthcare Ltd do?
Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products
Where is Sakar Healthcare Ltd (SAKAR) listed?
Sakar Healthcare Ltd trades as SAKAR on the NSE.
Which sector does Sakar Healthcare Ltd belong to?
Sakar Healthcare Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Sakar Healthcare Ltd?
Sakar Healthcare Ltd trades at a PE ratio of 60.39 as of 4 Nov 2026, on earnings per share of ₹16.22, against a book value of ₹155.5 per share.
What is the 52-week high and low of Sakar Healthcare Ltd?
Over the last 52 weeks Sakar Healthcare Ltd has traded between ₹352.5 and ₹1,229.85 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Sakar Healthcare Ltd?
Sakar Healthcare Ltd reported a return on equity of 9.99%. Its debt-to-equity ratio is 0.22.

Company Information

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products

Website sakarhealthcare.com
Listed 11 Apr 2019
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SAKAR.md for Sakar Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month